Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications

Antonio Lopez-Beltran, Ziya Kirkali, Liang Cheng, Lars Egevad, Juan C. Regueiro, Ana Blanca, Rodolfo Montironi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Most conventional anticancer drugs act by preventing cells from dividing or have toxic effects on dividing cells, but the toxic effects on the normal cells in the body limit the dosage to a level below that which is effective for complete response. There has been a search for more specific agents that have a much greater effect on cancer, rather than on normal cells. Several new anticancer agents are in early development, and some are in clinical practice. Many of these new therapies require histological or molecular pathological testing to determine the therapy effectiveness. Aspects of the new targeted therapies for specific cancers are therefore of increasing relevance to both molecular and anatomic pathologists, including the biology behind, the eligibility criteria (by histology or molecular assays), specimen requirements, response assessment, and biologic or histological aspects of secondary resistance. Methodologies in this field are immunohistochemistry and fluorescent in situ hybridization, but PCR-based methods have great potential. The role of the pathologist in applying all of these new therapeutic targets to urologic tumors remains limited at present time, but in the future it should parallel their role for other cancers where targeted therapy has been more successful. The current status of biological and clinicopathological aspects of targeted therapy in prevalent urologic tumors is reviewed.

Original languageEnglish
Pages (from-to)232-244
Number of pages13
JournalSeminars in Diagnostic Pathology
Volume25
Issue number4
DOIs
StatePublished - Nov 2008

Fingerprint

Biological Therapy
Neoplasms
Poisons
Therapeutics
Fluorescence In Situ Hybridization
Antineoplastic Agents
Histology
Immunohistochemistry
Polymerase Chain Reaction
Pharmaceutical Preparations

Keywords

  • Bladder cancer
  • Pathology
  • Prostate cancer
  • Renal cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Targeted therapies and biological modifiers in urologic tumors : pathobiology and clinical implications. / Lopez-Beltran, Antonio; Kirkali, Ziya; Cheng, Liang; Egevad, Lars; Regueiro, Juan C.; Blanca, Ana; Montironi, Rodolfo.

In: Seminars in Diagnostic Pathology, Vol. 25, No. 4, 11.2008, p. 232-244.

Research output: Contribution to journalArticle

Lopez-Beltran, Antonio ; Kirkali, Ziya ; Cheng, Liang ; Egevad, Lars ; Regueiro, Juan C. ; Blanca, Ana ; Montironi, Rodolfo. / Targeted therapies and biological modifiers in urologic tumors : pathobiology and clinical implications. In: Seminars in Diagnostic Pathology. 2008 ; Vol. 25, No. 4. pp. 232-244.
@article{65200c71183c47f0ada2b7cdd900c9d5,
title = "Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications",
abstract = "Most conventional anticancer drugs act by preventing cells from dividing or have toxic effects on dividing cells, but the toxic effects on the normal cells in the body limit the dosage to a level below that which is effective for complete response. There has been a search for more specific agents that have a much greater effect on cancer, rather than on normal cells. Several new anticancer agents are in early development, and some are in clinical practice. Many of these new therapies require histological or molecular pathological testing to determine the therapy effectiveness. Aspects of the new targeted therapies for specific cancers are therefore of increasing relevance to both molecular and anatomic pathologists, including the biology behind, the eligibility criteria (by histology or molecular assays), specimen requirements, response assessment, and biologic or histological aspects of secondary resistance. Methodologies in this field are immunohistochemistry and fluorescent in situ hybridization, but PCR-based methods have great potential. The role of the pathologist in applying all of these new therapeutic targets to urologic tumors remains limited at present time, but in the future it should parallel their role for other cancers where targeted therapy has been more successful. The current status of biological and clinicopathological aspects of targeted therapy in prevalent urologic tumors is reviewed.",
keywords = "Bladder cancer, Pathology, Prostate cancer, Renal cancer, Targeted therapy",
author = "Antonio Lopez-Beltran and Ziya Kirkali and Liang Cheng and Lars Egevad and Regueiro, {Juan C.} and Ana Blanca and Rodolfo Montironi",
year = "2008",
month = "11",
doi = "10.1053/j.semdp.2008.07.006",
language = "English",
volume = "25",
pages = "232--244",
journal = "Seminars in Diagnostic Pathology",
issn = "0740-2570",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Targeted therapies and biological modifiers in urologic tumors

T2 - pathobiology and clinical implications

AU - Lopez-Beltran, Antonio

AU - Kirkali, Ziya

AU - Cheng, Liang

AU - Egevad, Lars

AU - Regueiro, Juan C.

AU - Blanca, Ana

AU - Montironi, Rodolfo

PY - 2008/11

Y1 - 2008/11

N2 - Most conventional anticancer drugs act by preventing cells from dividing or have toxic effects on dividing cells, but the toxic effects on the normal cells in the body limit the dosage to a level below that which is effective for complete response. There has been a search for more specific agents that have a much greater effect on cancer, rather than on normal cells. Several new anticancer agents are in early development, and some are in clinical practice. Many of these new therapies require histological or molecular pathological testing to determine the therapy effectiveness. Aspects of the new targeted therapies for specific cancers are therefore of increasing relevance to both molecular and anatomic pathologists, including the biology behind, the eligibility criteria (by histology or molecular assays), specimen requirements, response assessment, and biologic or histological aspects of secondary resistance. Methodologies in this field are immunohistochemistry and fluorescent in situ hybridization, but PCR-based methods have great potential. The role of the pathologist in applying all of these new therapeutic targets to urologic tumors remains limited at present time, but in the future it should parallel their role for other cancers where targeted therapy has been more successful. The current status of biological and clinicopathological aspects of targeted therapy in prevalent urologic tumors is reviewed.

AB - Most conventional anticancer drugs act by preventing cells from dividing or have toxic effects on dividing cells, but the toxic effects on the normal cells in the body limit the dosage to a level below that which is effective for complete response. There has been a search for more specific agents that have a much greater effect on cancer, rather than on normal cells. Several new anticancer agents are in early development, and some are in clinical practice. Many of these new therapies require histological or molecular pathological testing to determine the therapy effectiveness. Aspects of the new targeted therapies for specific cancers are therefore of increasing relevance to both molecular and anatomic pathologists, including the biology behind, the eligibility criteria (by histology or molecular assays), specimen requirements, response assessment, and biologic or histological aspects of secondary resistance. Methodologies in this field are immunohistochemistry and fluorescent in situ hybridization, but PCR-based methods have great potential. The role of the pathologist in applying all of these new therapeutic targets to urologic tumors remains limited at present time, but in the future it should parallel their role for other cancers where targeted therapy has been more successful. The current status of biological and clinicopathological aspects of targeted therapy in prevalent urologic tumors is reviewed.

KW - Bladder cancer

KW - Pathology

KW - Prostate cancer

KW - Renal cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=53749086992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749086992&partnerID=8YFLogxK

U2 - 10.1053/j.semdp.2008.07.006

DO - 10.1053/j.semdp.2008.07.006

M3 - Article

C2 - 19013890

AN - SCOPUS:53749086992

VL - 25

SP - 232

EP - 244

JO - Seminars in Diagnostic Pathology

JF - Seminars in Diagnostic Pathology

SN - 0740-2570

IS - 4

ER -